Efficacy and safety of combination immunotherapy for treating advanced non-clear cell renal cell carcinoma: A multicenter retrospective study in Japan
The phase 3 CheckMate 214 trial demonstrates improved overall survival in treatment‑naïve advanced renal cell carcinoma patients receiving nivolumab plus ipilimumab compared with sunitinib.
Bizonyítékszint: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Kapcsolódó jelek
- Prognostic Value of the Modified Glasgow Prognostic Score in Patients with Metastatic Renal Cell Carcinoma Receiving Nivolumab as Second-Line Therapy
- A Review of Immunotherapy in Renal Cell Carcinoma: Current Landscape and Future Directions
- EAU 2025: State-of-the-Art Lecture: Neoadjuvant Strategies in Locally Advanced Renal Cancer
- Early detection of renal cell carcinoma: a novel cell-free DNA fragmentomics‑based liquid biopsy assay
- Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)